{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:40:25Z","timestamp":1785526825051,"version":"3.56.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2021R1C1C1012392"],"award-info":[{"award-number":["2021R1C1C1012392"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00211426"],"award-info":[{"award-number":["RS-2023-00211426"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2018R1A2B600292"],"award-info":[{"award-number":["2018R1A2B600292"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04436-6","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T16:53:36Z","timestamp":1779987216000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pertussis toxin-induced lymphocytosis shifts the tumor microenvironment toward immune activation via CXCL9 signaling"],"prefix":"10.1007","volume":"75","author":[{"given":"Jae-Keun","family":"Cho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyungmin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da-Yong","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Truc","family":"Do Thanh Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Woongyang","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Jin","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han-Sin","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"issue":"12","key":"4436_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med 50(12):1\u201311. https:\/\/doi.org\/10.1038\/s12276-018-0191-1","journal-title":"Exp Mol Med"},{"key":"4436_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.731798","volume":"12","author":"J Liu","year":"2021","unstructured":"Liu J, Chen Z, Li Y, Zhao W, Wu J, Zhang Z (2021) PD-1\/PD-L1 checkpoint inhibitors in tumor immunotherapy. Front Pharmacol 12:731798. https:\/\/doi.org\/10.3389\/fphar.2021.731798","journal-title":"Front Pharmacol"},{"issue":"7","key":"4436_CR3","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/s41416-021-01413-x","volume":"125","author":"C Pilard","year":"2021","unstructured":"Pilard C, Ancion M, Delvenne P, Jerusalem G, Hubert P, Herfs M (2021) Cancer immunotherapy: it\u2019s time to better predict patients\u2019 response. Br J Cancer 125(7):927\u2013938. https:\/\/doi.org\/10.1038\/s41416-021-01413-x","journal-title":"Br J Cancer"},{"issue":"5","key":"4436_CR4","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","volume":"27","author":"JH Strickler","year":"2021","unstructured":"Strickler JH, Hanks BA, Khasraw M (2021) Tumor mutational burden as a predictor of immunotherapy response: Is more always better? Clin Cancer Res 27(5):1236\u20131241. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3054","journal-title":"Clin Cancer Res"},{"issue":"2","key":"4436_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo Gagliato D, Kurzrock R (2021) The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell 39(2):154\u2013173. https:\/\/doi.org\/10.1016\/j.ccell.2020.10.001","journal-title":"Cancer Cell"},{"issue":"1","key":"4436_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003091","volume":"10","author":"R Cristescu","year":"2022","unstructured":"Cristescu R, Aurora-Garg D, Albright A et al (2022) Tumor mutational burden predicts the efficacy of Pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer 10(1):e003091. https:\/\/doi.org\/10.1136\/jitc-2021-003091","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4436_CR7","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10120-019-00999-9","volume":"23","author":"K Yamashita","year":"2020","unstructured":"Yamashita K, Iwatsuki M, Harada K et al (2020) Prognostic impacts of the Combined Positive Score and the Tumor Proportion Score for Programmed Death Ligand-1 expression by double immunohistochemical staining in patients with advanced gastric cancer. Gastric Cancer 23(1):95\u2013104. https:\/\/doi.org\/10.1007\/s10120-019-00999-9","journal-title":"Gastric Cancer"},{"issue":"11","key":"4436_CR8","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1136\/jclinpath-2020-206832","volume":"74","author":"P De Marchi","year":"2021","unstructured":"De Marchi P, Leal LF, Duval da Silva V, da Silva ECA, Cordeiro de Lima VC, Reis RM (2021) PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC). J Clin Pathol 74(11):735\u2013740. https:\/\/doi.org\/10.1136\/jclinpath-2020-206832","journal-title":"J Clin Pathol"},{"issue":"7","key":"4436_CR9","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1158\/1078-0432.CCR-20-2980","volume":"27","author":"ZA Wainberg","year":"2021","unstructured":"Wainberg ZA, Fuchs CS, Tabernero J et al (2021) Efficacy of Pembrolizumab monotherapy for advanced gastric\/gastroesophageal junction cancer with Programmed Death Ligand 1 Combined Positive Score >\/=10. Clin Cancer Res 27(7):1923\u20131931. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-2980","journal-title":"Clin Cancer Res"},{"issue":"6","key":"4436_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B et al (2014) Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst 106(6):dju124. https:\/\/doi.org\/10.1093\/jnci\/dju124","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"4436_CR11","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12916-020-01817-1","volume":"18","author":"MA Cupp","year":"2020","unstructured":"Cupp MA, Cariolou M, Tzoulaki I, Aune D, Evangelou E, Berlanga-Taylor AJ (2020) Neutrophil to lymphocyte ratio and cancer prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies. BMC Med 18(1):360. https:\/\/doi.org\/10.1186\/s12916-020-01817-1","journal-title":"BMC Med"},{"issue":"1","key":"4436_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56218-z","volume":"9","author":"R Howard","year":"2019","unstructured":"Howard R, Kanetsky PA, Egan KM (2019) Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Sci Rep 9(1):19673. https:\/\/doi.org\/10.1038\/s41598-019-56218-z","journal-title":"Sci Rep"},{"issue":"1","key":"4436_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s40425-019-0549-5","volume":"7","author":"C Menetrier-Caux","year":"2019","unstructured":"Menetrier-Caux C, Ray-Coquard I, Blay JY, Caux C (2019) Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines? J Immunother Cancer 7(1):85. https:\/\/doi.org\/10.1186\/s40425-019-0549-5","journal-title":"J Immunother Cancer"},{"issue":"13","key":"4436_CR14","doi-asserted-by":"publisher","first-page":"5383","DOI":"10.1158\/0008-5472.CAN-08-3845","volume":"69","author":"I Ray-Coquard","year":"2009","unstructured":"Ray-Coquard I, Cropet C, Van Glabbeke M et al (2009) Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res 69(13):5383\u20135391. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-3845","journal-title":"Cancer Res"},{"issue":"7","key":"4436_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103606","volume":"9","author":"K Takemura","year":"2024","unstructured":"Takemura K, Yuasa T, Lemelin A et al (2024) Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma receiving first-line combination immunotherapies: results from the International Metastatic Renal Cell Carcinoma Database Consortium. ESMO Open 9(7):103606. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103606","journal-title":"ESMO Open"},{"issue":"1","key":"4436_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s40425-018-0315-0","volume":"6","author":"AA Lalani","year":"2018","unstructured":"Lalani AA, Xie W, Martini DJ et al (2018) Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6(1):5. https:\/\/doi.org\/10.1186\/s40425-018-0315-0","journal-title":"J Immunother Cancer"},{"issue":"1","key":"4436_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1038\/s41467-021-20935-9","volume":"12","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D et al (2021) Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. Nat Commun 12(1):729. https:\/\/doi.org\/10.1038\/s41467-021-20935-9","journal-title":"Nat Commun"},{"issue":"5","key":"4436_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.ijrobp.2019.08.047","volume":"105","author":"Y Cho","year":"2019","unstructured":"Cho Y, Park S, Byun HK et al (2019) Impact of treatment-related lymphopenia on immunotherapy for advanced non-small cell lung cancer. Int J Radiat Oncol Biol Phys 105(5):1065\u20131073. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.08.047","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"4436_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133282","author":"D Tomsitz","year":"2022","unstructured":"Tomsitz D, Schlaak M, Zierold S, Pesch G, Schulz TU, Muller G, Zecha C, French LE, Heinzerling L (2022) Development of lymphopenia during therapy with immune checkpoint inhibitors is associated with poor outcome in metastatic cutaneous melanoma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers14133282","journal-title":"Cancers (Basel)"},{"issue":"7","key":"4436_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/femspd\/ftw087","volume":"74","author":"NH Carbonetti","year":"2016","unstructured":"Carbonetti NH (2016) Pertussis leukocytosis: mechanisms, clinical relevance and treatment. Pathog Dis 74(7):ftw087. https:\/\/doi.org\/10.1093\/femspd\/ftw087","journal-title":"Pathog Dis"},{"key":"4436_CR21","doi-asserted-by":"publisher","first-page":"S234","DOI":"10.1093\/infdis\/136.supplement.s234","volume":"136","author":"SI Morse","year":"1977","unstructured":"Morse SI (1977) Lymphocytosis-promoting factor of Bordetella pertussis: isolation, characterization, and biological activity. J Infect Dis 136:S234-238. https:\/\/doi.org\/10.1093\/infdis\/136.supplement.s234","journal-title":"J Infect Dis"},{"issue":"2","key":"4436_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8020217","volume":"8","author":"KK Dewan","year":"2020","unstructured":"Dewan KK, Linz B, DeRocco SE, Harvill ET (2020) Acellular pertussis vaccine components: today and tomorrow. Vaccines 8(2):217. https:\/\/doi.org\/10.3390\/vaccines8020217","journal-title":"Vaccines"},{"issue":"2","key":"4436_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1073\/pnas.1314688110","volume":"111","author":"JM Warfel","year":"2014","unstructured":"Warfel JM, Zimmerman LI, Merkel TJ (2014) Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci U S A 111(2):787\u2013792. https:\/\/doi.org\/10.1073\/pnas.1314688110","journal-title":"Proc Natl Acad Sci U S A"},{"key":"4436_CR24","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","volume":"4","author":"SI Pai","year":"2009","unstructured":"Pai SI, Westra WH (2009) Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annu Rev Pathol 4:49\u201370. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092158","journal-title":"Annu Rev Pathol"},{"issue":"2","key":"4436_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.tranon.2019.11.008","volume":"13","author":"F Perri","year":"2020","unstructured":"Perri F, Ionna F, Longo F, Della Vittoria Scarpati G, De Angelis C, Ottaiano A, Botti G, Caponigro F (2020) Immune response against head and neck cancer: biological mechanisms and implication on therapy. Transl Oncol 13(2):262\u2013274. https:\/\/doi.org\/10.1016\/j.tranon.2019.11.008","journal-title":"Transl Oncol"},{"issue":"11","key":"4436_CR26","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1158\/1078-0432.CCR-04-0054","volume":"10","author":"I Kuss","year":"2004","unstructured":"Kuss I, Hathaway B, Ferris RL, Gooding W, Whiteside TL (2004) Decreased absolute counts of T lymphocyte subsets and their relation to disease in squamous cell carcinoma of the head and neck. Clin Cancer Res 10(11):3755\u20133762. https:\/\/doi.org\/10.1158\/1078-0432.CCR-04-0054","journal-title":"Clin Cancer Res"},{"key":"4436_CR27","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3389\/fcell.2019.00052","volume":"7","author":"M Canning","year":"2019","unstructured":"Canning M, Guo G, Yu M, Myint C, Groves MW, Byrd JK, Cui Y (2019) Heterogeneity of the head and neck squamous cell carcinoma immune landscape and its impact on immunotherapy. Front Cell Dev Biol 7:52. https:\/\/doi.org\/10.3389\/fcell.2019.00052","journal-title":"Front Cell Dev Biol"},{"issue":"2","key":"4436_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000334","volume":"8","author":"YQ Wang","year":"2020","unstructured":"Wang YQ, Chen L, Mao YP et al (2020) Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology. J Immunother Cancer 8(2):e000334. https:\/\/doi.org\/10.1136\/jitc-2019-000334","journal-title":"J Immunother Cancer"},{"key":"4436_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01970","volume":"8","author":"M Metzemaekers","year":"2017","unstructured":"Metzemaekers M, Vanheule V, Janssens R, Struyf S, Proost P (2017) Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands. Front Immunol 8:1970. https:\/\/doi.org\/10.3389\/fimmu.2017.01970","journal-title":"Front Immunol"},{"key":"4436_CR30","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ctrv.2017.11.007","volume":"63","author":"R Tokunaga","year":"2018","unstructured":"Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, Soni S, McSkane M, Baba H, Lenz HJ (2018) CXCL9, CXCL10, CXCL11\/CXCR3 axis for immune activation - a target for novel cancer therapy. Cancer Treat Rev 63:40\u201347. https:\/\/doi.org\/10.1016\/j.ctrv.2017.11.007","journal-title":"Cancer Treat Rev"},{"issue":"9","key":"4436_CR31","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko K, Matsumura N, Hamanishi J, Horikawa N, Murakami R, Yamaguchi K, Yoshioka Y, Baba T, Konishi I, Mandai M (2015) IFN-gamma from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br J Cancer 112(9):1501\u20131509. https:\/\/doi.org\/10.1038\/bjc.2015.101","journal-title":"Br J Cancer"},{"issue":"1","key":"4436_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-07603-8","volume":"12","author":"MM Kroes","year":"2022","unstructured":"Kroes MM, Miranda-Bedate A, Jacobi RHJ, van Woudenbergh E, den Hartog G, van Putten JPM, de Wit J, Pinelli E (2022) Bordetella pertussis-infected innate immune cells drive the anti-pertussis response of human airway epithelium. Sci Rep 12(1):3622. https:\/\/doi.org\/10.1038\/s41598-022-07603-8","journal-title":"Sci Rep"},{"key":"4436_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/toxins14030187","author":"K Ernst","year":"2022","unstructured":"Ernst K (2022) Novel strategies to inhibit Pertussis toxin. Toxins (Basel). https:\/\/doi.org\/10.3390\/toxins14030187","journal-title":"Toxins (Basel)"},{"issue":"1","key":"4436_CR34","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s1369-5274(02)00006-1","volume":"6","author":"DL Burns","year":"2003","unstructured":"Burns DL (2003) Type IV transporters of pathogenic bacteria. Curr Opin Microbiol 6(1):29\u201334. https:\/\/doi.org\/10.1016\/s1369-5274(02)00006-1","journal-title":"Curr Opin Microbiol"},{"issue":"12","key":"4436_CR35","doi-asserted-by":"publisher","first-page":"3594","DOI":"10.1172\/JCI24609","volume":"115","author":"GS Kirimanjeswara","year":"2005","unstructured":"Kirimanjeswara GS, Agosto LM, Kennett MJ, Bjornstad ON, Harvill ET (2005) Pertussis toxin inhibits neutrophil recruitment to delay antibody-mediated clearance of Bordetella pertussis. J Clin Invest 115(12):3594\u20133601. https:\/\/doi.org\/10.1172\/JCI24609","journal-title":"J Clin Invest"},{"issue":"2","key":"4436_CR36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/0022-1759(91)90090-3","volume":"144","author":"H Verschueren","year":"1991","unstructured":"Verschueren H, Dewit J, Van der Wegen A, De Braekeleer J, Van Heule G, Dekegel D, De Baetselier P (1991) The lymphocytosis promoting action of Pertussis toxin can be mimicked in vitro. Holotoxin but not the B subunit inhibits invasion of human T lymphoma cells through fibroblast monolayers. J Immunol Methods 144(2):231\u2013240. https:\/\/doi.org\/10.1016\/0022-1759(91)90090-3","journal-title":"J Immunol Methods"},{"issue":"18","key":"4436_CR37","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.150532","volume":"6","author":"C Lyu","year":"2021","unstructured":"Lyu C, Ye Y, Lensing MM, Wagner KU, Weigel RJ, Chen S (2021) Targeting Gi\/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy. JCI Insight 6(18):e150532. https:\/\/doi.org\/10.1172\/jci.insight.150532","journal-title":"JCI Insight"},{"issue":"2","key":"4436_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.147","volume":"3","author":"H Li","year":"2022","unstructured":"Li H, Wu M, Zhao X (2022) Role of chemokine systems in cancer and inflammatory diseases. MedComm 3(2):e147. https:\/\/doi.org\/10.1002\/mco2.147","journal-title":"MedComm"},{"issue":"1","key":"4436_CR39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12865-020-00396-3","volume":"22","author":"W Xiu","year":"2021","unstructured":"Xiu W, Luo J (2021) CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling. BMC Immunol 22(1):3. https:\/\/doi.org\/10.1186\/s12865-020-00396-3","journal-title":"BMC Immunol"},{"key":"4436_CR40","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1200\/EDBK_240837","volume":"39","author":"CM Fares","year":"2019","unstructured":"Fares CM, Van Allen EM, Drake CG, Allison JP, Hu-Lieskovan S (2019) Mechanisms of resistance to immune checkpoint blockade: why does checkpoint inhibitor immunotherapy not work for all patients? Am Soc Clin Oncol Educ Book 39:147\u2013164. https:\/\/doi.org\/10.1200\/EDBK_240837","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"15","key":"4436_CR41","doi-asserted-by":"publisher","first-page":"7175","DOI":"10.7150\/thno.59056","volume":"11","author":"Z Shi","year":"2021","unstructured":"Shi Z, Shen J, Qiu J, Zhao Q, Hua K, Wang H (2021) CXCL10 potentiates immune checkpoint blockade therapy in homologous recombination-deficient tumors. Theranostics 11(15):7175\u20137187. https:\/\/doi.org\/10.7150\/thno.59056","journal-title":"Theranostics"},{"issue":"1","key":"4436_CR42","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12935-022-02604-z","volume":"22","author":"W Feng","year":"2022","unstructured":"Feng W, Lin A, Sun L, Wei T, Ying H, Zhang J, Luo P, Zhu W (2022) Activation of the chemokine receptor 3 pathway leads to a better response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma. Cancer Cell Int 22(1):186. https:\/\/doi.org\/10.1186\/s12935-022-02604-z","journal-title":"Cancer Cell Int"},{"issue":"3","key":"4436_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.12.010","volume":"13","author":"L Barrueto","year":"2020","unstructured":"Barrueto L, Caminero F, Cash L, Makris C, Lamichhane P, Deshmukh RR (2020) Resistance to checkpoint inhibition in cancer immunotherapy. Transl Oncol 13(3):100738. https:\/\/doi.org\/10.1016\/j.tranon.2019.12.010","journal-title":"Transl Oncol"},{"issue":"9","key":"4436_CR44","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s12276-024-01301-3","volume":"56","author":"SJ Im","year":"2024","unstructured":"Im SJ, Lee K, Ha SJ (2024) Harnessing IL-2 for immunotherapy against cancer and chronic infection: a historical perspective and emerging trends. Exp Mol Med 56(9):1900\u20131908. https:\/\/doi.org\/10.1038\/s12276-024-01301-3","journal-title":"Exp Mol Med"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04436-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04436-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:04:19Z","timestamp":1785521059000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04436-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":44,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["4436"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04436-6","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study followed international, national, and\/or institutional guidelines for humane animal treatment. It complied with relevant legislation, as approved by the Institutional Animal Care and Use Committee (IACUC) of Samsung Biomedical Research Center, Seoul, Korea (Approval Nos. 20201210001, 20211118001, and 20221208001).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"196"}}